Susan Y Bookheimer Selected Research

dicyanmethane (malononitrile)

1/2016	Modifiable Risk Factors and Brain Positron Emission Tomography Measures of Amyloid and Tau in Nondemented Adults with Memory Complaints.
1/2013	Vascular risk and FDDNP-PET influence cognitive performance.
7/2012	Self-reported memory impairment and brain PET of amyloid and tau in middle-aged and older adults without dementia.
2/2012	Prediction of cognitive decline by positron emission tomography of brain amyloid and tau.
6/2009	Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults.
5/2009	Differential FDDNP PET patterns in nondemented middle-aged and older adults.
1/2009	Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susan Y Bookheimer Research Topics

Disease

16	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 01/2002
10	Cognitive Dysfunction 12/2021 - 12/2006
7	Dementia (Dementias) 01/2023 - 01/2009
6	Amyloid Plaque 01/2016 - 12/2006
3	Autism Spectrum Disorder 01/2019 - 06/2012
3	Memory Disorders (Memory Loss) 01/2013 - 04/2006
2	Amyloidosis 01/2023 - 01/2023
2	Cerebral Cortical Thinning 01/2023 - 05/2011
2	Neurodevelopmental Disorders 11/2015 - 11/2010
1	Atrophy 01/2023
1	Insulin Resistance 01/2023
1	Schizophrenia (Dementia Praecox) 01/2023
1	Hypertension (High Blood Pressure) 07/2020
1	Heart Diseases (Heart Disease) 07/2020
1	Type 2 Diabetes Mellitus (MODY) 07/2020
1	Pain (Aches) 01/2020
1	Neurofibromatosis 1 (Neurofibromatosis Type I) 11/2015
1	Learning Disabilities (Learning Disability) 11/2015
1	Inborn Genetic Diseases (Disease, Hereditary) 11/2015
1	Brain Concussion (Cerebral Concussion) 02/2013
1	Stroke (Strokes) 01/2013
1	Bipolar Disorder (Manic Depressive Psychosis) 05/2011
1	Specific Language Disorder 11/2010
1	Autistic Disorder (Autism) 11/2010
1	Frontotemporal Dementia (Semantic Dementia) 02/2008

Drug/Important Bio-Agent (IBA)

9	Biomarkers (Surrogate Marker)IBA 01/2023 - 02/2008
8	Amyloid (Amyloid Fibrils)IBA 01/2023 - 12/2006
7	dicyanmethane (malononitrile)IBA 01/2016 - 01/2009
6	ApolipoproteinsIBA 11/2017 - 04/2006
4	Apolipoproteins E (ApoE)IBA 07/2017 - 01/2002
3	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 02/2008
3	FluorineIBA 02/2012 - 05/2009
2	CholesterolIBA 01/2023 - 07/2020
2	Apolipoprotein E4IBA 01/2009 - 04/2006
1	CarbohydratesIBA 01/2023
1	Insulin (Novolin)FDA Link 01/2023
1	Complement C4aIBA 01/2023
1	Neurofibromin 1 (Neurofibromin)IBA 11/2015
1	Flavin-Adenine Dinucleotide (FAD)IBA 12/2013
1	tau Proteins (tau Protein)IBA 02/2013
1	AntioxidantsIBA 01/2013
1	2- (1- (6- ((2- fluoroethyl)(methyl)amino)- 2- naphthyl)ethylidene)malononitrileIBA 02/2012
1	LithiumIBA 05/2011
1	Proteins (Proteins, Gene)FDA Link 11/2010
1	Celecoxib (Celebrex)FDA Link 12/2008
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 12/2008
1	VaccinesIBA 02/2008
1	Neurotransmitter Agents (Neurotransmitter)IBA 02/2008

Therapy/Procedure

2	Intravenous Injections 06/2009 - 01/2009
1	Carbohydrate-Restricted Diet (Low Carbohydrate Diet) 01/2023
1	Body Piercing (Piercing, Body) 01/2020